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Abstract
Objective: Insulin-like growth factor I (IGF-I) and dioxin-like polychlorobiphenyls (DL-PCBs) have been associated with the
pathogenesis of several diseases like cancer, diabetes and growth disorders. Because it has been suggested that
organohalogenated contaminants could influence IGF-I levels in adults, the potential relationship between DL-PCBs and
IGF-I serum levels was studied in 456 healthy adults from a representative sample of the general population of the Canary
Islands (Spain).
Design: Free circulating serum levels of IGF-I and IGFBP-3 were measured through an ELISA methodology, while the serum
levels of the 12 DL-PCBs congeners (IUPAC numbers # 77, 81, 105, 114, 118, 123, 126, 156, 157, 167, 169, and 189) were
measured by gas chromatography/mass spectrometry (GC-MS).
Results: DL-PCBs 156 and 167, Total DL-PCBs body burden (gPCBs: sum over the 12 measured DL-PCBs), and Total toxic
burden (in terms of toxic equivalence to dioxins: gTEQs) showed a trend of inverse association with IGF-I serum levels in the
whole studied population. After adjusting for potential confounders, including gender, body mass index (BMI), age, and IGF-
binding protein-3 (IGFBP-3), younger (18–45 years) women with lower BMI (,27 kg/m
2) and detectable levels of DL-PCB-
156 showed significantly lower IGF-I levels than those in the same age and BMI subgroup with non-detectable levels of DL-
PCB-156 (p,0.001). Similarly, gPCBs and gTEQs showed a tendency to an inverse association with IGF-I levels in the same
group of women (p=0.017 and p=0.019 respectively).
Conclusions: These findings suggest that DL-PCBs could be involved in the regulation of the IGF-system in a way possibly
influenced by gender, age and BMI. Although these results should be interpreted with caution, such circumstances could
contribute to explain the development of diseases associated to the IGF system.
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Introduction
Insulin-like growth factor-I (IGF-I) is an amino acid peptide
synthesized in the liver in response to growth hormone (GH). IGF-
I may circulate in one of two states, either free or bound to one of
six different binding proteins, with .90% bound to the IGF
binding protein 3 (IGFBP-3) [1]. The regulatory role of IGF-I on
cellular differentiation and proliferation, as well as on a number of
tissue-specific functions, is well known [2]. In addition, IGF-I has
been found to be involved in the development of a number of
diseases, such as diabetes, cancer, and growth disorders [3,4,5].
Serum levels of IGF-I are influenced by gender, age, body mass
index (BMI), and dietary and lifestyle factors [6]. IGF-I levels show
sexual dimorphism, with higher levels in men than in women,
especially in older people [7], although the influence of gender is
not completely understood [8]. An evident inverse relationship
between age and IGF-I levels has been described in adults [9,10].
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reported [6,11] and recently published studies indicate that such
association is non-linear [12]. Dietary factors may play a role on
IGF-I levels [13]. It was recently proposed that chemical pollutants
in food and environment (i.e. organochlorine pollutants) should
also be taken into account [14]. Exposure to environmental
pollutants, such as dioxins and polychlorobiphenyls (PCBs), may
affect IGF-I homeostasis [15,16] although not yet demonstrated
such associations in humans.
PCBs are environmentally and biologically persistent polyhalo-
genated aromatic hydrocarbons [17]. PCBs are mixtures of up to
209 different congeners, although only 36 of them are environ-
mentally relevant [18]. Since they are lipid-soluble and resistant to
chemical and biological degradation, PCBs intake leads to life-long
bioaccumulation, both in animals and humans, and to biomagni-
fication through the food chain [17]. Due to their persistence both
in the environment and living organisms, these substances were
banned in 1970s and 1980s in most Western countries [19].
PCBs have been detected in biological samples from popula-
tions all over the world [20,21,22]. A number of factors seem to
influence PCBs serum levels in humans (e.g. gender, age, BMI and
diet or lifestyle factors). In an earlier study [23], we reported the
overall PCBs serum levels in a representative sample of the same
population involved in this study, namely adults living in the
Spanish archipelago of the Canary Islands. The serum levels of
DL-PCBs residues in this Canarian population were lower than
those reported for other Western populations [23].
Exposure to PCBs has been associated with several health
outcomes, especially when the so-called dioxin-like PCBs (DL-
PCBs) are involved – 12 PCB congeners with toxic effects similar
to those of dioxins [24]. Since 1987, PCBs have been considered as
probable human carcinogens (Group 2A) by the International
Agency for Research on Cancer (IARC) [25]. Moreover,
evidences show that exposure to these chemicals may be associated
with alterations in memory, learning, and other neuropsycholog-
ical effects [26], diabetes [27,28], and restricted growth in children
[29]. It was recently suggested that these chemicals could also
induce disturbances in growing hormone axis activity and growth
rate [30].
The aim of this study was to explore the association between
DL-PCBs and IGF-I serum levels in healthy subjects from a
population previously studied about the levels of contamination by
PCBs. [23].
Materials and Methods
Subjects group and collection of blood-samples
This study included 456 adult subjects (203 men and 253
women) aged 18 to 73 years, who were enrolled during the Canary
Islands Nutritional Survey (ENCA). The ENCA nutritional survey
was conducted in 1997–1998 in the seven major Islands of the
Canary Archipelago (Spain). The sample was stratified in two
stages, and it was representative of the population between 6 and
75 years of age for both genders. Participants were randomly
selected from the official census. A total of 1747 healthy subjects
participated in the first part of the study. This part consisted in two
individual interviews with questions about dietary variables, life
habits, and health condition. The participants had blood samples
extracted after 12-h fasting in order to determine biochemical
parameters and the presence of DL-PCBs. A total of 783 subjects
participated in the biochemical part (participation rate, 44.8%).
Data about DL-PCB residues in the adult subgroup of subjects
were available in 456 people [31]. All subjects received and signed
a written informed consent prior to blood extraction. Only
subjects who signed the informed consent were included. The
study was approved by the Research and Ethics Committee of the
Complejo Hospitalario Universitario Insular-Materno Infantil (Las
Palmas de Gran Canaria, Spain). The participants were not
compensated for their collaboration in any way. Table 1 shows the
characteristics of the population under study.
Determination of IGF-I and IGFBP-3
Free circulating serum levels of IGF-I and IGFBP-3 were
measured the subgroup of people with data about serum levels of
DL-PCBs (456 adult people), in the Department of Laboratory
Tests from the Hospital Universitario de Gran Canaria Dr. Negrı ´n
(Canary Islands, Spain) using a commercially available enzyme
linked immune sorbent assay (ELISA) kit (Diagnostic Systems
Laboratories, Webster, TX, USA); a useful assay widely used with
large sample sizes [9,14,32,33]. All the samples were analyzed in
duplicate. Data of IGF-I serum levels were available for all the
study population. The overall intra-batch coefficients of variation
were lower than 10% for both proteins. The average inter-batch
coefficients of variation were 9% for IGF-I and 12% for IGFBP-3.
The coefficients of variation detected coincided with those
reported by the manufacturer.
Analytical procedure: sample preparation and laboratory
tests
The sample preparation and laboratory tests procedures are
described elsewhere [23]. Briefly, serum aliquots (2–3 ml) were
subjected to solid-phase extraction and subsequent gas chroma-
tography/mass spectrometry (GC/MS) with appropriate internal
standards. The analytes in this study were the DL-PCBs congeners
with IUPAC numbers # 77, 81, 105, 114, 118, 123, 126, 156,
157, 167, 169, and 189. Chromatography was performed with
Thermo-Finnigan TRACE DSQ GC/MS equipment. Standards
and samples were injected (2 ml) in the splitless mode. Tetra-
chloro-m-xylene was used as a surrogate and PCB 202 as the
internal standard. The limit of quantification (LOQ) for DL-PCB
congener 118 was 0.010 ng/ml; while the LOQ for the rest of
analytes was 0.001 ng/ml. The standard analytes for this study
were purchased from Dr. Ehrenstorfer (Riedel-de Hagen, Sigma-
Aldrich Laborchemikalien GmbH, Germany).
Serum DL-PCBs concentration values measured by chroma-
tography were lipid-adjusted (lipid-adjusted serum concentrations
Table 1. Biological characteristics of the studied population,
N (%).
Characteristic Total Male Female
456 (100) 203 (44.5) 253 (55.5)
Age (years)
18–34 107 (17.6) 47 (23.2) 60 (23.7)
35–50 139 (22.9) 57 (28.1) 82 (32.4)
50–65 141 (23.2) 64 (31.5) 77 (30.4)
.65 69 (11.4) 35 (17.2) 34 (13.5)
BMI (kg/m
2)
,18.5 10 (2.3) 3 (1.5) 7 (2.9)
18.5–24.99 164 (35.9) 72 (35.4) 92 (36.4)
25–29.99 175 (38.4) 79 (39.0) 96 (38.0)
.30 107 (23.4) 49 (24.1) 58 (22.7)
doi:10.1371/journal.pone.0038213.t001
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[34]. Total cholesterol and triglycerides were measured with an
automatic Hitachi Analyzer 717 (Boehringer Manheim, IN, USA).
Total serum lipids were estimated by using the formula established
by Phillips [35].
Throughout this work, Total DL-PCBs body burden (gDL-
PCBs) expresses the sum over the measured serum levels of the 12
DL-PCBs; potential toxicity (in terms of toxic equivalent to
dioxins: TEQs) was estimated using the toxicity equivalent factors
(TEF) reviewed by the World Health Organization (WHO) in
2005 [36]; and Total TEQs (gTEQs) expresses the sum over the
TEQs corresponding to the measured serum DL-PCBs.
Statistical analysis
Database management and statistical analysis were performed
with the PASW Statistics v 17.0 statistical software (SPSS Inc.,
Chicago, IL, USA). Since the serum levels of PCBs, IGF-I and
IGFBP-3 did not follow normal distributions, results were
expressed as median and 5
th and 95
th percentiles. Between-group
differences in PCB levels were analyzed with the non-parametric
Mann–Whitney U-test and the Kruskal Wallis test. Correlation
between PCB levels and continuous variables was analyzed with
the Spearman’s correlation coefficient. Multivariate analysis was
performed using the variance component analysis stratifying the
population according to gender, age (above or below the mean: 46
years for women, and 47 years for men) and BMI (above or below
the mean: 27 kg/m
2 for both), and after adjusting by IGFBP-3,
and gender or age or BMI [9,32,37,38,39]. Because of the large
number of serum samples which present DL-PCBs serum values
below the LOQ, samples were considered to be either detectable
(D-sample) or non-detectable (ND-sample) for every congener and
were introduced into the model as categorical factor. However,
because of the large number of samples with gDL-PCBs and
gTEQs above the LOQ, these variables were categorized into
gender-age-BMI-specific tertiles (lowest gDL-PCBs and gTEQs
values in the first tertile, intermediate values in the second tertile,
and highest values in the third tertile) and introduced into the
model as categorical factors. P values,0.05 (two-tails) were
considered to be statistically significant.
Results
The studied population included healthy adults with similar
average age and BMI values for men and women (47.7 years and
26.9 kg/m
2 for men; 46.4 years and 26.9 kg/m
2 for women).
Table 2 shows that the median free circulating IGF-I values did
not differ significantly between genders, while evidencing the
physiological profile of serum IGF-I levels, which significantly
decrease with increasing age (p,0.001 for both genders; data not
shown) and with increasing BMI (p=0.004 for men and p,0.001
for women; data not shown). Free circulating serum levels of
IGFBP-3 were significantly different according to gender and age
(Table 2).
Subjects with non-detectable levels of DL-PCBs were younger
than those showing detectable levels of DL-PCBs (p,0.0001, 42.2
vs. 50.1 years old, respectively). As a consequence, subjects
showing undetectable DL-PCBs serum levels had higher IGF-I
median values than those showing detectable DL-PCBs serum
levels (p=0.003, 173.0 vs. 153 ng/ml, respectively).
A positive correlation between age and DL-PCBs was evident
(R=0.327, p,0.0001). This association was also observed
indistinctly among men (R=0.374, p,0.0001) and women
(R=0.274, p,0.0001). However, we did not find any association
related to BMI.
Three out of the total 12 measured DL-PCB congeners (# 77,
105 and 114) were not found in any of the samples, while
congeners 156 and 167 were detected in more than 40% of
samples, with percentile 95
th concentrations as high as 10.9 and
8.7 ng/g lipid, respectively (Table 3). However, the most relevant
congeners in terms of high TEF values, PCBs 126 and 169, were
detected in a low percentage of samples (0.7 and 6.1%,
respectively). As previously described [23], the median TEQ
value corresponding to the measured gDL-PCBs was low (0.1 pg/
g lipid). However, it should be highlighted that TEQs levels
reached values of 40.2 pg/g lipid in serum samples included in
percentile 95
th (Table 3).
The serum levels of IGF-I and DL-PCBs showed a trend of
inverse association in the whole population. Thus, serum IGF-I
values decreased with increasing PCB-156, PCB-167, gDL-PCBs
and gTEQs (R=20.210, p,0.001; R=20.140, p=0.006;
R=20.196, p,0.001; and R=20.184 p=0.001, respectively).
The relationship between IGF-I and the above variables was
evident in a neperian log-transformed scatter plot (Figures 1A, 1B,
1C and 1D). This trend was also evident in a separate analysis of
data from men (p,0.05 for all comparisons) and women (p,0.01
for all comparisons) (not shown).
Since gender, age, BMI and IGFBP-3 play an important role in
IGF-I serum levels, and gender, age and BMI also seem to be
important determinants of DL-PCBs distribution [23], we carried
out a multivariate analysis (stratifying the population sample by
gender, age and BMI, and adjusting for IGFBP-3 and age, gender
or BMI) in order to evaluate the potential role of DL-PCBs on
IGF-I serum levels. Results of this analysis showed the same
negative-relationship tendency described above both for men and
women, although some associations failed to reach significance
Table 2. Distribution of IGF-I and IGFBP-3 (ng/ml) in the
studied population.
Characteristic
IGF-I
[median (p5-p95)]
IGFBP-3
[median (p5-p95)]
Whole series 157.0 (73.0–277.5) 3998.0 (2607.0–5775.0)
Gender
Male 159.0 (87.0–278.0) 3938.0 (2427.8–5853.6)
Female 155.5 (70.9–273.4) 4044.0 (2835.2–5770.8)
P 0.428 0.025
Age (years)
18–34 201.0 (125.2–320.8) 4205.5 (3094.4–6067.4)
35–50 170.0 (101.6–246.4) 4074.0 (2918.3–5912.0)
50–65 145.0 (64.3–237.5) 3763.0 (2318.5–5528.7)
.65 133.0 (39.0–227.0) 3588.0 (2286.9–5260.5)
P ,0.001 ,0.001
BMI (kg/m
2)
,18.5 210.0 (113.0–307.0) 4814.5 (3110.0–5410.0)
18.5–24.99 178.0 (100.4–304.8) 3939.0 (2627.3–5825.1)
25–29.99 151.0 (83.4–263.3) 3998.0 (2563.8–5543.6)
.30 140.0 (57.7–243.6) 3978.0 (2470.8–5952.0)
P ,0.001 0.135
Abbreviations: p5 represents the 5th percentile and p95 represents the 95th
percentile.
P values correspond to comparison between characteristics, for IGF-I and IGFBP-
3 (Kruskal-Wallis test).
doi:10.1371/journal.pone.0038213.t002
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statistically significant difference was found in any of the subgroups
of men (data not shown). However, it has to be highlighted the
clear inverse relationship between IGF-I values and DL-PCBs
serum levels evidenced in the youngest subgroup of women. As
shown in Table 4, younger women with lower BMI (18–46 years
and BMI ,27 kg/m
2) who showed undetectable levels of DL-
PCB-156 had higher IGF-I serum levels than younger women with
lower BMI who showed detectable levels of this contaminant
(p,0.001). Furthermore, a clear inverse association between IGF-I
and gDL-PCBs serum values was evident in this age-BMI-
subgroup of women; thus, this subtype of women in tertile 1 had
higher IGF-I serum levels than those in tertiles 2 and 3 (p=0.017);
and consequently, gTEQs showed a similar inverse relationship.
Similar results were observed for TEQs; the lowest gTEQs (tertile
1) had higher IGF-I serum levels than those with higher gTEQs
(tertiles 2 and 3) (p=0.019). This inverse association was observed
even when PCBs were considered as a continuous variable. Thus,
in this subset women, serum IGF-I values decreased with
increasing PCB-156, gDL-PCBs and gTEQs (R=20.329,
p,0.005; R=20.317, p=0.008; and R=20.303 p=0.011,
respectively).
Discussion
The GH-IGF-I system is affected by environmental changes and
is a probable target for endocrine disrupting compounds that may
impair many physiological processes. As far as we know, this is the
first study to assess the potential effects of DL-PCB exposure on
IGF-I, in a general population sample. Our results suggest a
modest inverse association between DL-PCBs and IGF-I serum
levels, in a subgroup of population formed by young women with
low BMI. Nonetheless, due to the fact that this is a cross-sectional
study, our results pointing to the possibility that DL-PCBS could
exert a negative modulation on GH/IGF system must be taken as
an indication of a potential causal relationship.
IGF-I serum levels vary extraordinarily with age [9,10].
Conversely, a positive correlation between age and serum PCB
levels was observed [23,40,41]. In this study, we observed an age-
dependent inverse association between IGF-I serum levels and
DL-PCB 156, gDL-PCBs and gTEQs, where young women with
BMI less than 27 and higher DL-PCBs contamination had lower
levels of serum IGF-I.
The IGF-system shows sexual dimorphism [7], although the
influence of gender is still not clearly understood [8]. Increases in
GH and IGF-1 levels are positively correlated with sex steroids in
both sexes during puberty and the influence of these steroids on
the GH–IGF axis is believed to be a major determinant in the
growth spurt at this time of life [42]. No significant difference
between genders in serum IGF was found in our population.
Dioxin-like compounds are considered to be endocrine disrupt-
ers [43,44,45]. In human male serum, high levels of DL-PCBs
were associated with decreased estrogen receptor-mediated
activity and increased dioxin-like activity [46]. Our results suggest
that the potential negative role of DL-PCBs on the IGF system is
influenced by gender and age, with the most evident results in a
women-subgroup that assumedly have the highest estrogen levels
(women between 18–45 years). The fact that women at their fertile
age (18–45 years) are most susceptible to the negative modulation
of DL-PCBs on the IGF system is of concern, because of the
potential hazard of DL-PCB toxic effects on fetuses at critical
stages of development are well documented [47].
The influence of BMI on serum IGF-I levels is well known
[6,11,12]. In a recent study, BMI values with the highest IGF-I
serum levels were reported in men with BMI of 22.5–25 kg/m
2
and in women with 27.5–30 kg/m
2 [39]. The Canary Islands
population has a rather high proportion of over-weighted and
obese people (more than 60%; see Table 1) [48] and subjects with
higher BMIs have higher levels of DL-PCBs [23]. Our present
Table 3. Distribution of DL-PCBs concentrations (ng/g lipid) and TEQs (pg/g lipid) in adult blood serum in the population of the
Canary Islands.
Congener Concentration median (p5–p95) TEQs median(p5–p95) (%)
DL-PCB (Non-ortho)
PCB-77 ,LOQ N.A. 0.0
PCB-81 0.0 (0.0–0.0) 0.0 (0.0–0.0) 4.6
PCB-126 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.7
PCB-169 0.0 (0.0–1.3) 0.0 (0.0–38.9) 6.1
DL-PCB (Mono-ortho)
PCB-105 ,LOQ N.A. 0.0
PCB-114 ,LOQ N.A. 0.0
PCB-118 0.0 (0.0–23.1) 0.1 (0.0–0.7) 18.9
PCB-123 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.9
PCB-156 0.0 (0.0–10.9) 0.0 (0.0–0.3) 48.5
PCB-157 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.2
PCB-167 0.0 (0.0–8.7) 0.0 (0.0–0.3) 43.9
PCB-189 0.0 (0.0–0.0) 0.0 (0.0–0.0) 1.5
SDL-PCBs 2.8 (0.0–56.8) 60.3
STEQs 0.0 (0.0–0.4) 0.1 (0.0–40.2) 60.9
Abbreviations: LOQ, limit of quantification; N.A., not applicable. p5 and p95 represent the 5
th and 95
th percentiles respectively. gDL-PCB: sum over the dioxin-like PCB
levels (IUPAC numbers 77, 81, 105, 114, 118, 123, 126, 156, 157, 167, 169, and 189). gTEQs: sum over TEQs for the DL-PCBs.
doi:10.1371/journal.pone.0038213.t003
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PCBs serum levels. Thus, only women with high IGF-I levels, i.e.
women between 18–45 years old, with BMI below the population
mean (27 kg/m
2) showed an evident inverse association between
DL-PCBs and IGF-I serum levels.
There is a crosslink between the IGF-system and other
hormonal systems. IGF-I and insulin have complementary roles
in the regulation of blood glucose [49]. Interestingly, animal and
human cell studies suggest that diverse PCBs and dioxins alter
glucose and insulin metabolism. Moreover, PCB 156 and other
DL-PCBs have been associated with higher risk of developing type
2 diabetes mellitus [28,50,51,52]. It can be speculated that the
negative association between DL-PCBs and the IGF system
activity might be related with the low IGF-I serum levels described
for diabetic patients. Furthermore, an inverse association between
PCB 156 and serum levels of thyroid hormones has been described
in one study [53]. The interaction between DL-PCBs, the IGF-
system and other hormones could play a potential role in the
development of important chronic diseases.
Our results agree with previous studies in the observation that
serum IGF-I levels may be modulated by exogenous factors, such
as environmental pollutants [14,38,54,55]. These results agree
with some previous reports of our research group showing lower
IGF-I serum levels in subjects with higher levels of organochlorine
pesticides in a way that is highly influenced by gender, age and the
involved chemical or combination of chemicals [14,33]. The
relative importance of the effects of pollutants on biological
systems is not well understood, especially when complex chemical
mixtures are taken into account [56]. Because of such complexity,
the mixture of different components with agonistic/antagonistic
effects and the limited knowledge about the biological effects of
most PCBs may hamper the interpretation of our findings.
Because the liver is the main source of circulating IGF-I, the
inverse relationship between PCBs and IGF could be the
consequence of a direct effect of these environmental pollutants
on the liver [54]. In this context, cytochromes CYP1A1 and
CYP2B are activated by DL-PCB congeners, including PCB156,
through the binding with the aryl hydrocarbon receptor (AhR)
[57].
Nutrition is a major regulator of circulating IGF-I [9]. The
presence of environmental pollutants in food has been recently
documented in our region [58]. Diet seems to be the major DL-
Figure 1. Scatter plot of log IGF-I serum levels and log of DL-PCB 156 (A), PCB 167 (B), gDL-PCBs (C), and gTEQs serum levels (D).
doi:10.1371/journal.pone.0038213.g001
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currently considered to be the major source, according to the
European Food Safety Agency in 2010 [59]. Although fish
consumption is low in the Canary Islands, the daily intake of dairy
products is particularly high [48]. Interestingly, serum IGF-I levels
have been found to be highly correlated with the intake of dairy
products [60]. Because of this situation, further studies on the
influence of dietary habits on the DL-PCBs-IGF relationship are
worth the effort.
In summary, we found a significant negative association
between serum levels of DL-PCBs and the IGF system in younger
women with lower levels of BMI. This result suggests that DL-
PCBs, especially DL-PCB-156, could negatively modulate the IGF
system in this subgroup of patients. Although some PCBs are
known to be hormonally active agents, a plausible mechanism for
their effects on the IGF system has not been elucidated yet, a
purpose that appears especially challenging when other well-
known determining factors – such as gender, age, BMI or diet –
are considered. Since both DL-PCBs exposure and the IGF system
seem to play a role in some prevalent chronic diseases, studying
the effects of DL-PCBs on the IGF system seems to deserve further
effort, especially taking into account the implications of this issue
for public health decisions. However, the present results concern
only a subset of individuals, and other alternative explanation
should be taken into account; thus, these results should be
interpreted with caution, and the study must be considered as a
hypothesis-generating study. Further prospective experiments are
needed to confirm those results.
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